MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
MetaVia (Nasdaq: MTVA) announced on December 22, 2025 that it received Nasdaq notice dated December 19, 2025 confirming the company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2).
The notice states MetaVia also satisfies all other applicable Nasdaq listing criteria and that the related listing matter has been closed on the Nasdaq Capital Market.
Positive
- Regained Nasdaq compliance with minimum bid price on Dec 19, 2025
- Listing matter formally closed by Nasdaq for continued Nasdaq Capital Market listing
Negative
- None.
News Market Reaction
On the day this news was published, MTVA gained 11.60%, reflecting a significant positive market reaction. Argus tracked a peak move of +7.3% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $23M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer moves are mixed, with names like PULM down 34.35% and SYBX up 2.56%. Only THAR showed momentum scanner activity, up 12.03% without news, suggesting MTVA’s compliance update is company-specific rather than a sector-wide driver.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Reverse stock split | Negative | -20.1% | 1-for-11 reverse split aimed at meeting Nasdaq listing requirements. |
| Nov 07 | Phase 2a data | Positive | +6.8% | Positive Phase 2a vanoglipel data in presumed MASH at AASLD 2025. |
| Nov 06 | Earnings and update | Positive | -15.0% | Q3 2025 results and pipeline update including DA-1726 and vanoglipel. |
| Nov 04 | Conference data | Positive | +8.0% | Phase 1 and preclinical DA-1726 data presented at ObesityWeek 2025. |
| Oct 27 | Poster announcement | Neutral | -1.4% | Announcement of vanoglipel poster presentation at AASLD Liver Meeting. |
Positive clinical and data presentations have often seen aligned positive reactions, while financial/structural actions like earnings and reverse splits have produced selling pressure.
Over the past few months, MetaVia has balanced clinical progress with listing and capital structure actions. A 1-for-11 reverse split on Dec 4, 2025 led to a -20.07% move, reflecting pressure around listing compliance. Positive DA-1726 and vanoglipel data in early November saw aligned gains of 8% and 6.85%. Q3 2025 results on Nov 6 coincided with a -15% reaction. Today’s notice that Nasdaq minimum bid compliance has been regained closes the loop on those prior listing concerns.
Market Pulse Summary
The stock surged +11.6% in the session following this news. A strong positive reaction aligns with the resolution of a key listing overhang. Regaining Nasdaq’s minimum bid compliance under Rule 5550(a)(2) follows earlier steps like the 1-for-11 reverse split and may have reduced perceived delisting risk. Historically, MetaVia’s clinical wins drew buying while financial and structural actions were sold. If gains became extended, investors could have watched whether interest persisted given the stock’s position below its 200-day moving average.
Key Terms
nasdaq's minimum bid price requirement regulatory
the nasdaq capital market regulatory
AI-generated analysis. Not financial advice.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Interim Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302647630.html
SOURCE MetaVia Inc.
FAQ
What did MetaVia (MTVA) announce on December 22, 2025 about Nasdaq compliance?
Does MetaVia (MTVA) remain listed on the Nasdaq Capital Market after Dec 19, 2025?
What Nasdaq rule did MetaVia (MTVA) regain compliance with on Dec 19, 2025?
Will MetaVia (MTVA) face immediate delisting after the Nasdaq notice on Dec 19, 2025?
Where can investors find the Nasdaq compliance notice for MetaVia (MTVA)?
